Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.

Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Abstract Text:

Despite significant advances in supportive care in oncology, many patients with cancer still experience chemotherapy- induced nausea and vomiting (CINV). Historically, there were only 3 neurotransmitter receptors (dopamine D2, cannabinoid- 1, and 5-hydroxytryptamine-3) that were the known targets for antiemetic therapy. Major advances in the management of chemotherapy-induced emesis were seen with the introduction of 5-hydroxytryptamine-3 receptor antagonists, which include palonosetron, ondansetron, tropisetron, dolasetron, and granisetron. However, recently, selective inhibitors of substance P have shown promising activity in the management of CINV in patients with cancer. Substance P mediates a number of biologic effects by binding to a specific neuroreceptor, neurokinin-1 (NK-1). Among the NK-1 receptor antagonists, aprepitant has been approved for the treatment of CINV. Currently, several other NK-1 receptor antagonists, including casopitant, vestipitant, netupitant, and SCH619734, are undergoing clinical evaluation for the prevention of CINV in patients with a variety of malignancies. The clinical potential of these novel NK-1 receptor antagonists and their respective ongoing clinical trials for the management of chemotherapy-induced emesis are discussed briefly herein.

Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Supportive cancer therapy

VOLUME: 3

Page Numbers: 140-2

Journal Abbreviation:

ISSN: 1543-2912

DAY: 1

MONTH: Apr

YEAR: 2006

Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101223683

Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.

AFFILIATION: CIG Media Group, LP, Dallas, TX.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Support Cancer Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis Related Publications

• Birth and re-birth.
• Causes and treatment of ulnar nerve paralysis.
• Chemotherapy-induced nausea and vomiting.
• EXPERIENCES WITH THE THOMPSON QUADRICEPSPLASTY.
• Evidence that a polymorphism within the 3'UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer.
• Fowl peritoneal exudate cells: Collection and use for the macrophage migration inhibition test.
• Functional effects of a common single-nucleotide polymorphism (GPX4c718t) in the glutathione peroxidase 4 gene: interaction with sex.
• Fungous infections; the superficial and deep mycoses.
• Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study).
• INTRA-UTERINE AMPUTATIONS AND ANNULAR LIMB DEFECTS IN SINGAPORE.
• Marasmus.
• Neurosis in the factory.
• No evidence of the Chlamydia trachomatis variant in the UK.
• Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.
• Nutrigenomics and selenium: gene expression patterns, physiological targets, and genetics.
• Palliative care in the cancer patient.
• Preschool children and physical activity a review of correlates.
• Staufen1 is expressed in preimplantation mouse embryos and is required for embryonic stem cell differentiation.
• Supplementation of healthy volunteers with nutritionally relevant amounts of selenium increases the expression of lymphocyte protein biosynthesis genes.
• Targeting of transcripts encoding membrane proteins in polarized epithelia: RNA-protein binding studies of the SGLT1 3'-UTR.
• The management of primary adenocarcinoma of the vermiform appendix.
• The mental health status of Chinese rural-urban migrant workers : comparison with permanent urban and rural dwellers.